

Barbara De Moerloose

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3568338/publications.pdf>

Version: 2024-02-01

103
papers

7,073
citations

230014

27
h-index

68831

81
g-index

104
all docs

104
docs citations

104
times ranked

11102
citing authors

#	ARTICLE	IF	CITATIONS
1	Guideline for management of non-Down syndrome neonates with a myeloproliferative disease on behalf of the I-BFM AML Study Group and EWOG-MDS. <i>Haematologica</i> , 2022, 107, 759-764.	1.7	3
2	Clinical outcomes of second relapsed and refractory first relapsed paediatric AML : A retrospective study within the NOPHOâ€š SHIP consortium. <i>British Journal of Haematology</i> , 2022, , .	1.2	5
3	Novel Insights on the Use of L-Asparaginase as an Efficient and Safe Anti-Cancer Therapy. <i>Cancers</i> , 2022, 14, 902.	1.7	39
4	Brachytherapy for Pediatric Patients at Gustave Roussy Cancer Campus: A Model of International Cooperation for Highly Specialized Treatments. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 602-613.	0.4	11
5	Tisagenlecleucel in pediatric and young adult patients with Down syndrome-associated relapsed/refractory acute lymphoblastic leukemia. <i>Leukemia</i> , 2022, 36, 1508-1515.	3.3	21
6	Familial hemophagocytic lymphohistiocytosis type 3 presenting as neonatal cholestasis and splenomegaly. <i>Pediatric Allergy and Immunology</i> , 2022, 33, e13774.	1.1	1
7	CD19 CAR T-cells for pediatric relapsed acute lymphoblastic leukemia with active CNS involvement: a retrospective international study. <i>Leukemia</i> , 2022, 36, 1525-1532.	3.3	27
8	Deciphering the Non-Coding RNA Landscape of Pediatric Acute Myeloid Leukemia. <i>Cancers</i> , 2022, 14, 2098.	1.7	2
9	Deciphering molecular heterogeneity in pediatric AML using a cancer vs. normal transcriptomic approach. <i>Pediatric Research</i> , 2021, 89, 1695-1705.	1.1	8
10	Features and outcome of chronic myeloid leukemia at very young age: Data from the International Pediatric Chronic Myeloid Leukemia Registry. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28706.	0.8	6
11	Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapy. <i>Blood Advances</i> , 2021, 5, 593-601.	2.5	28
12	CAR-T treatment of pediatric AML: a long and winding road. <i>Blood</i> , 2021, 137, 1004-1006.	0.6	5
13	Long non-coding RNAs as novel therapeutic targets in juvenile myelomonocytic leukemia. <i>Scientific Reports</i> , 2021, 11, 2801.	1.6	8
14	RUNX2 regulates leukemic cell metabolism and chemotaxis in high-risk T cell acute lymphoblastic leukemia. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	20
15	TARP as antigen in cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3061-3068.	2.0	2
16	Hematopoietic stem cell transplantation in children and adolescents with GATA2-related myelodysplastic syndrome. <i>Bone Marrow Transplantation</i> , 2021, 56, 2732-2741.	1.3	24
17	Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia. , 2021, 9, e002287.		24
18	The variable biological signature of refractory cytopenia of childhood (RCC), a retrospective EWOG-MDS study. <i>Leukemia Research</i> , 2021, 108, 106652.	0.4	2

#	ARTICLE	IF	CITATIONS
19	Clinical evolution, genetic landscape and trajectories of clonal hematopoiesis in SAMD9/SAMD9L syndromes. <i>Nature Medicine</i> , 2021, 27, 1806-1817.	15.2	79
20	TARP is an immunotherapeutic target in acute myeloid leukemia expressed in the leukemic stem cell compartment. <i>Haematologica</i> , 2020, 105, 1306-1316.	1.7	9
21	Lymphoblastic predominance of blastic phase in children with chronic myeloid leukaemia treated with imatinib: A report from the I-CML-Ped Study. <i>European Journal of Cancer</i> , 2020, 137, 224-234.	1.3	9
22	The altered transcriptome of pediatric myelodysplastic syndrome revealed by RNA sequencing. <i>Journal of Hematology and Oncology</i> , 2020, 13, 135.	6.9	4
23	Synonymous GATA2 mutations result in selective loss of mutated RNA and are common in patients with GATA2 deficiency. <i>Leukemia</i> , 2020, 34, 2673-2687.	3.3	38
24	Prospective, real-time monitoring of pegylated <i>Escherichia coli</i> and <i>Erwinia</i> asparaginase therapy in childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma in Belgium. <i>British Journal of Haematology</i> , 2020, 190, 105-114.	1.2	12
25	Clinical Significance of TARP Expression in Pediatric Acute Myeloid Leukemia. <i>HemaSphere</i> , 2020, 4, e346.	1.2	3
26	CircRNAs Dysregulated in Juvenile Myelomonocytic Leukemia: CircMCTP1 Stands Out. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 613540.	1.8	12
27	Outcome of (Novel) Subgroups in 1257 Pediatric Patients with KMT2A-Rearranged Acute Myeloid Leukemia (AML) and the Significance of Minimal Residual Disease (MRD) Status: A Retrospective Study By the I-BFM-SG. <i>Blood</i> , 2020, 136, 26-27.	0.6	1
28	Safety and Efficacy of CD19 CAR T-Cells for Pediatric Relapsed Acute Lymphoblastic Leukemia with Active CNS Involvement. <i>Blood</i> , 2020, 136, 1-1.	0.6	2
29	Tisagenlecleucel (Tisa) for relapsed/refractory (r/r) acute lymphoblastic leukemia (ALL): B2001X study focusing on prior exposure to blinatumomab (BLINA) and inotuzumab (INO).. <i>Journal of Clinical Oncology</i> , 2020, 38, 10518-10518.	0.8	10
30	Aging of Preleukemic Thymocytes Drives CpG Island Hypermethylation in T-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2020, 136, 28-29.	0.6	0
31	Phase I dose-escalation study of volasertib in pediatric patients with acute leukemia or advanced solid tumors. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27900.	0.8	6
32	Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1710-1718.	5.1	65
33	Noonan syndrome-associated myeloproliferative disorder with somatically acquired monosomy 7: impact on clinical decision making. <i>British Journal of Haematology</i> , 2019, 187, E83-E86.	1.2	8
34	Associations between pretherapeutic body mass index, outcome, and cytogenetic abnormalities in pediatric acute myeloid leukemia. <i>Cancer Medicine</i> , 2019, 8, 6634-6643.	1.3	8
35	Response-guided chemotherapy for pediatric acute myeloid leukemia without hematopoietic stem cell transplantation in first complete remission: Results from protocol DB AML01. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27605.	0.8	26
36	Results of successive EORTC-CLG 58881 and 58951 trials in paediatric T-cell acute lymphoblastic leukaemia (ALL). <i>British Journal of Haematology</i> , 2019, 186, 741-753.	1.2	15

#	ARTICLE	IF	CITATIONS
37	Use of granulocyte colony-stimulating factor and risk of relapse in pediatric patients treated for acute myeloid leukemia according to NOPHO-AML 2004 and DB AML-01. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27701.	0.8	10
38	An effective modestly intensive re-induction regimen with bortezomib in relapsed or refractory paediatric acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2018, 181, 523-527.	1.2	12
39	RNA-based FLT3-ITD allelic ratio is associated with outcome and ex vivo response to FLT3 inhibitors in pediatric AML. <i>Blood</i> , 2018, 131, 2485-2489.	0.6	22
40	Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. <i>New England Journal of Medicine</i> , 2018, 378, 439-448.	13.9	3,680
41	Oral microbiota reduce wound healing capacity of epithelial monolayers, irrespective of the presence of 5-fluorouracil. <i>Experimental Biology and Medicine</i> , 2018, 243, 350-360.	1.1	15
42	A Novel Asparaginase with low Glutaminase Coactivity Is Highly Efficacious against Both T- and B-cell Acute Lymphoblastic Leukemias <i>In Vivo</i> . <i>Cancer Research</i> , 2018, 78, 1549-1560.	0.4	67
43	Recurrently affected genes in juvenile myelomonocytic leukaemia. <i>British Journal of Haematology</i> , 2018, 182, 135-138.	1.2	5
44	Leukaemic stem cell load at diagnosis predicts the development of relapse in young acute myeloid leukaemia patients. <i>British Journal of Haematology</i> , 2018, 183, 512-516.	1.2	27
45	Cancer-related mRNA expression analysis using a novel flow cytometry-based assay. <i>Cytometry Part B - Clinical Cytometry</i> , 2018, 94, 565-575.	0.7	4
46	Complex and monosomal karyotype are distinct cytogenetic entities with an adverse prognostic impact in paediatric acute myeloid leukaemia. A NOPHO-DBH-AML study. <i>British Journal of Haematology</i> , 2018, 183, 618-628.	1.2	8
47	Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. <i>Nature Medicine</i> , 2018, 24, 1504-1506.	15.2	393
48	Prognostic impact of t(16;21)(p11;q22) and t(16;21)(q24;q22) in pediatric AML: a retrospective study by the I-BFM Study Group. <i>Blood</i> , 2018, 132, 1584-1592.	0.6	45
49	The genetic basis and cell of origin of mixed phenotype acute leukaemia. <i>Nature</i> , 2018, 562, 373-379.	13.7	236
50	Associations between neutrophil recovery time, infections and relapse in pediatric acute myeloid leukemia. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27231.	0.8	8
51	Differences in infection prophylaxis measures between paediatric acute myeloid leukaemia study groups within the international Berlin-Frankfurt-Münster (IFM) study group. <i>British Journal of Haematology</i> , 2018, 183, 87-95.	1.2	8
52	The long non-coding RNA landscape in juvenile myelomonocytic leukemia. <i>Haematologica</i> , 2018, 103, e501-e504.	1.7	13
53	Updated Analysis of the Efficacy and Safety of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed/Refractory (r/r) Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018, 132, 895-895.	0.6	70
54	Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF pH4. <i>International Journal of Pharmaceutical Compounding</i> , 2018, 22, 516-526.	0.0	2

#	ARTICLE	IF	CITATIONS
55	Additional cytogenetic abnormalities and variant t(9;22) at the diagnosis of childhood chronic myeloid leukemia: The experience of the International Registry for Chronic Myeloid Leukemia in children and adolescents. <i>Cancer</i> , 2017, 123, 3609-3616.	2.0	25
56	Characteristics and outcome in patients with central nervous system involvement treated in European pediatric acute myeloid leukemia study groups. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26664.	0.8	14
57	Prognostic discrimination based on the EUTOS long-term survival score within the International Registry for Chronic Myeloid Leukemia in children and adolescents. <i>Haematologica</i> , 2017, 102, 1704-1708.	1.7	40
58	Digital Multiplex Ligation-Dependent Probe Amplification for Detection of Key Copy Number Alterations in T- and B-Cell Lymphoblastic Leukemia. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 659-672.	1.2	30
59	Prolonged <i>versus</i> standard native <i>E. coli</i> asparaginase therapy in childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma: final results of the EORTC-CLG randomized phase III trial 58951. <i>Haematologica</i> , 2017, 102, 1727-1738.	1.7	22
60	RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia. <i>Nature Communications</i> , 2017, 8, 2126.	5.8	91
61	Patient-reported quality of life (QOL) following CTL019 in pediatric and young adult patients (pts) with relapsed/refractory (r/r) b-cell acute lymphoblastic leukemia (B-ALL). <i>Journal of Clinical Oncology</i> , 2017, 35, 10523-10523.	0.8	2
62	Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescents. <i>Blood</i> , 2016, 127, 1387-1397.	0.6	304
63	LIN28B overexpression defines a novel fetal-like subgroup of juvenile myelomonocytic leukemia. <i>Blood</i> , 2016, 127, 1163-1172.	0.6	48
64	LIN28B is over-expressed in specific subtypes of pediatric leukemia and regulates lncRNA H19. <i>Haematologica</i> , 2016, 101, e240-e244.	1.7	18
65	Therapy with low-dose azacitidine for MDS in children and young adults: a retrospective analysis of the EWOG-MDS study group. <i>British Journal of Haematology</i> , 2016, 172, 930-936.	1.2	31
66	Impact of Somatic Mutations on the Outcome of Children and Adolescents with Therapy-Related Myelodysplastic Syndrome. <i>Blood</i> , 2016, 128, 3162-3162.	0.6	3
67	RPPA-Based Protein Profiling Reveals Enhanced PI3K/AKT/mTOR Signaling in ETV6/RUNX1-Positive Acute Lymphoblastic Leukemia Patients with Low CD200 Expression. <i>Blood</i> , 2016, 128, 890-890.	0.6	1
68	Unique long non-coding RNA expression signature in ETV6/RUNX1-driven B-cell precursor acute lymphoblastic leukemia. <i>Oncotarget</i> , 2016, 7, 73769-73780.	0.8	30
69	Prognostic Discrimination of Children and Adolescents with Chronic Myeloid Leukemia Based on the EUTOS Long Term Survival (ELTS) Score. <i>Blood</i> , 2016, 128, 626-626.	0.6	1
70	The H3K27me3 demethylase UTX is a gender-specific tumor suppressor in T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2015, 125, 13-21.	0.6	168
71	Heterogeneous cytogenetic subgroups and outcomes in childhood acute megakaryoblastic leukemia: a retrospective international study. <i>Blood</i> , 2015, 126, 1575-1584.	0.6	69
72	Criteria for evaluating response and outcome in clinical trials for children with juvenile myelomonocytic leukemia. <i>Haematologica</i> , 2015, 100, 17-22.	1.7	43

#	ARTICLE	IF	CITATIONS
73	Bone marrow immunophenotyping by flow cytometry in refractory cytopenia of childhood. <i>Haematologica</i> , 2015, 100, 315-323.	1.7	38
74	Novel biological insights in T-cell acute lymphoblastic leukemia. <i>Experimental Hematology</i> , 2015, 43, 625-639.	0.2	97
75	Molecular basis and clinical significance of genetic aberrations in B-cell precursor acute lymphoblastic leukemia. <i>Experimental Hematology</i> , 2015, 43, 640-653.	0.2	20
76	Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2015, 33, 2949-2962.	0.8	277
77	CD200/BTLA deletions in pediatric precursor B-cell acute lymphoblastic leukemia treated according to the EORTC-CLG 58951 protocol. <i>Haematologica</i> , 2015, 100, 1311-1319.	1.7	8
78	<i>RASA4</i> undergoes DNA hypermethylation in resistant juvenile myelomonocytic leukemia. <i>Epigenetics</i> , 2014, 9, 1252-1260.	1.3	34
79	MicroRNA-128-3p is a novel oncomiR targeting PHF6 in T-cell acute lymphoblastic leukemia. <i>Haematologica</i> , 2014, 99, 1326-1333.	1.7	55
80	Dexamethasone (6 mg/m ² /day) and prednisolone (60 mg/m ² /day) were equally effective as induction therapy for childhood acute lymphoblastic leukemia in the EORTC CLG 58951 randomized trial. <i>Haematologica</i> , 2014, 99, 1220-1227.	1.7	74
81	ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2014, 124, 3738-3747.	0.6	198
82	Anthracycline Type during Induction Associated with Outcome in Pediatric t(8;21) and Inv(16) AML. <i>Blood</i> , 2014, 124, 11-11.	0.6	12
83	Results of a Feasibility and Phase II Study on Bortezomib (BTZ) in Pediatric Multiply Relapsed or Refractory Acute Lymphoblastic Leukemia: Complete Hematological Responses with a Modestly Intensive Regimen Including BTZ. <i>Blood</i> , 2014, 124, 2290-2290.	0.6	1
84	Prognostic Relevance of CD200/Btla Deletions in Pediatric Precursor-B Cell Acute Lymphoblastic Leukemia Treated According to the EORTC-CLG 58951 Protocol. <i>Blood</i> , 2014, 124, 2394-2394.	0.6	0
85	Clinical Impact of Additional Cytogenetic Aberrations, cKIT- and RAS Mutations and Other Factors in Pediatric t(8;21)-AML. <i>Blood</i> , 2014, 124, 481-481.	0.6	0
86	Pediatric Acute Megakaryoblastic Leukemia without Down Syndrome: A Retrospective Study by the International Berlin-Frankfurt-Munster Study Group (I-BFMSG). <i>Blood</i> , 2014, 124, 3670-3670.	0.6	0
87	Bone Marrow Immunophenotyping By Flow Cytometry in Refractory Cytopenia of Childhood. <i>Blood</i> , 2014, 124, 1916-1916.	0.6	0
88	Low CNS Relapse Incidence without Radiotherapy and Improvement of Outcome: Results of Subsequent EORTC-CLG 58881 and 58951 Trials in Pediatric T-Cell Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2012, 120, 133-133.	0.6	4
89	Prolonged E. Coli Asparaginase Therapy Does Not Improve Significantly the Outcome for Children with Low and Average Risk Acute Lymphoblastic Leukemia (ALL) and Non Hodgkin Lymphoma (NHL): Final Report of the EORTC-CLG Randomized Phase III Trial 58951. <i>Blood</i> , 2012, 120, 134-134.	0.6	1
90	Unexpected High Frequency of GATA2 Mutations in Children with Non-Familial MDS and Monosomy 7. <i>Blood</i> , 2012, 120, 1699-1699.	0.6	7

#	ARTICLE	IF	CITATIONS
91	JMML Revisited: Role and Outcome of Hematopoietic Stem Cell Transplantation in Subtypes of Juvenile Myelomonocytic Leukemia (JMML). <i>Blood</i> , 2012, 120, 955-955.	0.6	4
92	Molecular Aberrations in 107 Children with Myelodysplastic Syndrome (MDS). <i>Blood</i> , 2012, 120, 2802-2802.	0.6	0
93	Pediatric Acute Myeloid Leukemia with t(8;16)(p11;p13): A Distinct Clinical and Biological Entity. Results of a Collaborative Study by the International Berlin-Frankfurt-Munster AML Study Group. <i>Blood</i> , 2012, 120, 2516-2516.	0.6	0
94	Similar Efficacy and Toxicity Profile for Idarubicin and Mitoxantrone in Induction and Intensification Treatment of Children with Acute Myeloid Leukemia (AML) or Myelodysplasia (MDS): Long-Term Results of the EORTC-CLG Randomized Phase III Trial 58921. <i>Blood</i> , 2011, 118, 2615-2615.	0.6	2
95	IER3 Expression in Childhood Myelodysplastic Syndrome. <i>Blood</i> , 2011, 118, 3817-3817.	0.6	0
96	Mutations of the Spliceosome Complex Genes Occur In Adult Patients but Are Very Rare In Children with Myeloid Neoplasia. <i>Blood</i> , 2011, 118, 2797-2797.	0.6	0
97	Therapy-Related Myelodysplastic Syndrome Following Treatment for Childhood Acute Lymphoblastic Leukemia: Outcome of Patients Registered in the EWOG-MDS 98/06 Studies. <i>Blood</i> , 2011, 118, 4130-4130.	0.6	0
98	Improved outcome with pulses of vincristine and corticosteroids in continuation therapy of children with average risk acute lymphoblastic leukemia (ALL) and lymphoblastic non-Hodgkin lymphoma (NHL): report of the EORTC randomized phase 3 trial 58951. <i>Blood</i> , 2010, 116, 36-44.	0.6	58
99	Refractory Cytopenia In Childhood (RCC) with Normal Karyotype Is Unlikely to Progress to Advanced MDS Under a Watch and Wait Strategy. <i>Blood</i> , 2010, 116, 4007-4007.	0.6	6
100	Improved Outcome with Pulses of Vincristine and Steroids in Continuation Therapy of Children with Average Risk Acute Lymphoblastic Leukemia (ALL) and Non Hodgkin Lymphoma (NHL): Final Report of the EORTC Randomized Phase III Trial 58951. <i>Blood</i> , 2008, 112, 11-11.	0.6	52
101	The Combined Analysis of P-Glycoprotein Expression and Activity Predicts Outcome in Childhood Acute Lymphoblastic Leukemia. <i>Pediatric Hematology and Oncology</i> , 2003, 20, 381-391.	0.3	10
102	The Combined Analysis of P-Glycoprotein Expression and Activity Predicts Outcome in Childhood Acute Lymphoblastic Leukemia. <i>Pediatric Hematology and Oncology</i> , 2003, 20, 381-391.	0.3	3
103	The combined analysis of P-glycoprotein expression and activity predicts outcome in childhood acute lymphoblastic leukemia. <i>Pediatric Hematology and Oncology</i> , 2003, 20, 381-91.	0.3	2